Antibody drug conjugate technology specialist ImmunoGen Inc. has added $60m to its balance sheet via the divestiture of one asset to Debiopharm International SA and the amendment of a multi-product licensing agreement with Sanofi.
Sanofi, Debiopharm Deals Buy ImmunoGen Extra Time
ImmunoGen has turned around two cash-generation deals in a week as it seeks to extend its funding and narrow its focus. It has sold one asset to Debiopharm and foregone future royalties on five products licensed to Sanofi in exchange for an upfront lump sum.
More from Deals
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
More from Business
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.